NORP
US Government Inks $113 Million Deal with Siga to Enhance Smallpox and Mpox Reserves
US government, Siga, smallpox, mpox, Tpoxx, procurement deal, public health
FDA Issues Warning Letter to Indian CDMO Brassica for Data Falsification and Poor Hygiene Practices
FDA, Warning Letter, Brassica Pharma, Data Falsification, Poor Hygiene, Indian CDMO, CGMP Violations
GSK’s Dovato Matches Efficacy of Gilead’s Biktarvy with Less Weight Gain in HIV Trial
GSK, Dovato, Gilead, Biktarvy, HIV, weight gain, Spanish trial, PASO DOBLE, ViiV Healthcare
Novo Nordisk Invests $4.1 Billion in New US Manufacturing Site, Abandoning Irish Plans
Novo Nordisk, US manufacturing site, obesity drugs, fill-finish facility, Clayton, NC, Irish build
Revolutionary Gene Therapy Advancements: Early Trial Results from Leading Biotech Companies
ASGCT24, gene therapy, early trial results, Freeline, Rocket, Creyon, biotech companies, genetic diseases, hemophilia, liver diseases, Parkinson’s disease.
Bristol Myers and Cellares Collaborate on Global CAR-T Manufacturing Deal
Bristol Myers, Cellares, CAR-T, biopharma, manufacturing partners, diversification, global deal
BMS-Cellares Collaboration Spotlights U.S.-China Biopharma Rivalry
BMS, Cellares, CAR-T, collaboration, U.S.-China tensions, biopharma rivalry, cell therapy, cancer treatment.
Novartis Reevaluates Chinese Contractor Ties Amidst US Biosecurity Concerns
Novartis, Chinese contractors, US biosecurity, CFO, review, relationships, crackdown
BMS Expands CAR-T Therapy Capabilities with Strategic $380 Million Investment in Cellares
BMS, Bristol Myers Squibb, Cellares, CAR-T therapy, cell therapy, cancer treatment, biotechnology, investment, capacity expansion, manufacturing, automation.
Sage Therapeutics’ Dalzanemdor Outcomes Amid Parkinson’s Miss
Sage Therapeutics Dalzanemdor Parkinson